IndustryCompany release

Ionis cuts 2026 Tryngolza sales guidance to about $50M as sHTG launch lags

🇺🇸 Ionis Pharmaceuticals Inc (IONS) · Mon 09 Nov 2026

Ionis lowered its full-year Tryngolza outlook, citing slower-than-expected uptake in severe hypertriglyceridemia, while reaffirming other guidance and launching Zanvastro in Alexander disease.

Ionis Pharmaceuticals reported third-quarter 2026 results on 9 November, reducing its full-year sales guidance for Tryngolza (olezarsen) to around $50 million. The company attributed the cut to a slower-than-expected ramp in the launch for severe hypertriglyceridemia (sHTG).

Other guidance was left unchanged. Ionis reaffirmed its Dawnzera (donidalorsen) sales outlook of $110 million to $120 million, as well as its guidance for total revenue, operating loss and cash. Third-quarter revenue came in at $243 million.

The company also launched Zanvastro (zilganersen) for Alexander disease. The summary provided does not give further detail on the launch, such as pricing, markets or patient numbers.

On the regulatory front, Ionis noted a positive CHMP opinion for Tryngolza in sHTG. A final European Commission decision is expected in the fourth quarter of 2026. As general context, the Commission usually adopts a decision after a positive CHMP opinion, which then allows marketing in EU member states.

What it means for your team

  • Market-access teams should note that the US sHTG launch is tracking below company expectations, which is relevant for payer and uptake planning in the indication.
  • Regulatory teams should watch for the European Commission decision on Tryngolza in sHTG, which Ionis expects in Q4 2026.
  • The reaffirmed Dawnzera guidance and the Zanvastro launch show Ionis broadening its commercial portfolio beyond Tryngolza.

Company's press release (SEC filing): Ionis Pharmaceuticals Inc ↗

Article written by VigiEye from the official source (Ionis Pharmaceuticals Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →